IBDEI1OL ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,26871,2)
;;=^5003799
;;^UTILITY(U,$J,358.3,26872,0)
;;=G25.79^^110^1293^9
;;^UTILITY(U,$J,358.3,26872,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26872,1,3,0)
;;=3^Medication-Induced Movement Disorder,Other
;;^UTILITY(U,$J,358.3,26872,1,4,0)
;;=4^G25.79
;;^UTILITY(U,$J,358.3,26872,2)
;;=^5003800
;;^UTILITY(U,$J,358.3,26873,0)
;;=T43.205A^^110^1293^4
;;^UTILITY(U,$J,358.3,26873,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26873,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
;;^UTILITY(U,$J,358.3,26873,1,4,0)
;;=4^T43.205A
;;^UTILITY(U,$J,358.3,26873,2)
;;=^5050540
;;^UTILITY(U,$J,358.3,26874,0)
;;=T43.205D^^110^1293^5
;;^UTILITY(U,$J,358.3,26874,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26874,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
;;^UTILITY(U,$J,358.3,26874,1,4,0)
;;=4^T43.205D
;;^UTILITY(U,$J,358.3,26874,2)
;;=^5050541
;;^UTILITY(U,$J,358.3,26875,0)
;;=T43.205S^^110^1293^6
;;^UTILITY(U,$J,358.3,26875,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26875,1,3,0)
;;=3^Antidepressant Discontinuation Syndrome,Sequela
;;^UTILITY(U,$J,358.3,26875,1,4,0)
;;=4^T43.205S
;;^UTILITY(U,$J,358.3,26875,2)
;;=^5050542
;;^UTILITY(U,$J,358.3,26876,0)
;;=G25.71^^110^1293^7
;;^UTILITY(U,$J,358.3,26876,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26876,1,3,0)
;;=3^Medication-Induced Acute Akathisia
;;^UTILITY(U,$J,358.3,26876,1,4,0)
;;=4^G25.71
;;^UTILITY(U,$J,358.3,26876,2)
;;=^5003799
;;^UTILITY(U,$J,358.3,26877,0)
;;=G24.02^^110^1293^8
;;^UTILITY(U,$J,358.3,26877,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26877,1,3,0)
;;=3^Medication-Induced Acute Dystonia
;;^UTILITY(U,$J,358.3,26877,1,4,0)
;;=4^G24.02
;;^UTILITY(U,$J,358.3,26877,2)
;;=^5003785
;;^UTILITY(U,$J,358.3,26878,0)
;;=G21.0^^110^1293^12
;;^UTILITY(U,$J,358.3,26878,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26878,1,3,0)
;;=3^Neuroleptic Malignant Syndrome
;;^UTILITY(U,$J,358.3,26878,1,4,0)
;;=4^G21.0
;;^UTILITY(U,$J,358.3,26878,2)
;;=^5003771
;;^UTILITY(U,$J,358.3,26879,0)
;;=T50.905A^^110^1293^1
;;^UTILITY(U,$J,358.3,26879,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26879,1,3,0)
;;=3^Adverse Effect of Medication,Other,Init Encntr
;;^UTILITY(U,$J,358.3,26879,1,4,0)
;;=4^T50.905A
;;^UTILITY(U,$J,358.3,26879,2)
;;=^5052160
;;^UTILITY(U,$J,358.3,26880,0)
;;=T50.905S^^110^1293^2
;;^UTILITY(U,$J,358.3,26880,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26880,1,3,0)
;;=3^Adverse Effect of Medication,Other,Sequela
;;^UTILITY(U,$J,358.3,26880,1,4,0)
;;=4^T50.905S
;;^UTILITY(U,$J,358.3,26880,2)
;;=^5052162
;;^UTILITY(U,$J,358.3,26881,0)
;;=T50.905D^^110^1293^3
;;^UTILITY(U,$J,358.3,26881,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26881,1,3,0)
;;=3^Adverse Effect of Medication,Other,Subseq Encntr
;;^UTILITY(U,$J,358.3,26881,1,4,0)
;;=4^T50.905D
;;^UTILITY(U,$J,358.3,26881,2)
;;=^5052161
;;^UTILITY(U,$J,358.3,26882,0)
;;=F45.22^^110^1294^1
;;^UTILITY(U,$J,358.3,26882,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26882,1,3,0)
;;=3^Body Dysmorphic D/O
;;^UTILITY(U,$J,358.3,26882,1,4,0)
;;=4^F45.22
;;^UTILITY(U,$J,358.3,26882,2)
;;=^5003588
;;^UTILITY(U,$J,358.3,26883,0)
;;=F63.3^^110^1294^8
;;^UTILITY(U,$J,358.3,26883,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,26883,1,3,0)
;;=3^Trichotillomania (Hair-Pulling D/O)
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1OL 3755 printed Sep 23, 2025@19:48:46 Page 2
IBDEI1OL ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,26871,2)
+2 ;;=^5003799
+3 ;;^UTILITY(U,$J,358.3,26872,0)
+4 ;;=G25.79^^110^1293^9
+5 ;;^UTILITY(U,$J,358.3,26872,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,26872,1,3,0)
+8 ;;=3^Medication-Induced Movement Disorder,Other
+9 ;;^UTILITY(U,$J,358.3,26872,1,4,0)
+10 ;;=4^G25.79
+11 ;;^UTILITY(U,$J,358.3,26872,2)
+12 ;;=^5003800
+13 ;;^UTILITY(U,$J,358.3,26873,0)
+14 ;;=T43.205A^^110^1293^4
+15 ;;^UTILITY(U,$J,358.3,26873,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,26873,1,3,0)
+18 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
+19 ;;^UTILITY(U,$J,358.3,26873,1,4,0)
+20 ;;=4^T43.205A
+21 ;;^UTILITY(U,$J,358.3,26873,2)
+22 ;;=^5050540
+23 ;;^UTILITY(U,$J,358.3,26874,0)
+24 ;;=T43.205D^^110^1293^5
+25 ;;^UTILITY(U,$J,358.3,26874,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,26874,1,3,0)
+28 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
+29 ;;^UTILITY(U,$J,358.3,26874,1,4,0)
+30 ;;=4^T43.205D
+31 ;;^UTILITY(U,$J,358.3,26874,2)
+32 ;;=^5050541
+33 ;;^UTILITY(U,$J,358.3,26875,0)
+34 ;;=T43.205S^^110^1293^6
+35 ;;^UTILITY(U,$J,358.3,26875,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,26875,1,3,0)
+38 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
+39 ;;^UTILITY(U,$J,358.3,26875,1,4,0)
+40 ;;=4^T43.205S
+41 ;;^UTILITY(U,$J,358.3,26875,2)
+42 ;;=^5050542
+43 ;;^UTILITY(U,$J,358.3,26876,0)
+44 ;;=G25.71^^110^1293^7
+45 ;;^UTILITY(U,$J,358.3,26876,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,26876,1,3,0)
+48 ;;=3^Medication-Induced Acute Akathisia
+49 ;;^UTILITY(U,$J,358.3,26876,1,4,0)
+50 ;;=4^G25.71
+51 ;;^UTILITY(U,$J,358.3,26876,2)
+52 ;;=^5003799
+53 ;;^UTILITY(U,$J,358.3,26877,0)
+54 ;;=G24.02^^110^1293^8
+55 ;;^UTILITY(U,$J,358.3,26877,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,26877,1,3,0)
+58 ;;=3^Medication-Induced Acute Dystonia
+59 ;;^UTILITY(U,$J,358.3,26877,1,4,0)
+60 ;;=4^G24.02
+61 ;;^UTILITY(U,$J,358.3,26877,2)
+62 ;;=^5003785
+63 ;;^UTILITY(U,$J,358.3,26878,0)
+64 ;;=G21.0^^110^1293^12
+65 ;;^UTILITY(U,$J,358.3,26878,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,26878,1,3,0)
+68 ;;=3^Neuroleptic Malignant Syndrome
+69 ;;^UTILITY(U,$J,358.3,26878,1,4,0)
+70 ;;=4^G21.0
+71 ;;^UTILITY(U,$J,358.3,26878,2)
+72 ;;=^5003771
+73 ;;^UTILITY(U,$J,358.3,26879,0)
+74 ;;=T50.905A^^110^1293^1
+75 ;;^UTILITY(U,$J,358.3,26879,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,26879,1,3,0)
+78 ;;=3^Adverse Effect of Medication,Other,Init Encntr
+79 ;;^UTILITY(U,$J,358.3,26879,1,4,0)
+80 ;;=4^T50.905A
+81 ;;^UTILITY(U,$J,358.3,26879,2)
+82 ;;=^5052160
+83 ;;^UTILITY(U,$J,358.3,26880,0)
+84 ;;=T50.905S^^110^1293^2
+85 ;;^UTILITY(U,$J,358.3,26880,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,26880,1,3,0)
+88 ;;=3^Adverse Effect of Medication,Other,Sequela
+89 ;;^UTILITY(U,$J,358.3,26880,1,4,0)
+90 ;;=4^T50.905S
+91 ;;^UTILITY(U,$J,358.3,26880,2)
+92 ;;=^5052162
+93 ;;^UTILITY(U,$J,358.3,26881,0)
+94 ;;=T50.905D^^110^1293^3
+95 ;;^UTILITY(U,$J,358.3,26881,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,26881,1,3,0)
+98 ;;=3^Adverse Effect of Medication,Other,Subseq Encntr
+99 ;;^UTILITY(U,$J,358.3,26881,1,4,0)
+100 ;;=4^T50.905D
+101 ;;^UTILITY(U,$J,358.3,26881,2)
+102 ;;=^5052161
+103 ;;^UTILITY(U,$J,358.3,26882,0)
+104 ;;=F45.22^^110^1294^1
+105 ;;^UTILITY(U,$J,358.3,26882,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,26882,1,3,0)
+108 ;;=3^Body Dysmorphic D/O
+109 ;;^UTILITY(U,$J,358.3,26882,1,4,0)
+110 ;;=4^F45.22
+111 ;;^UTILITY(U,$J,358.3,26882,2)
+112 ;;=^5003588
+113 ;;^UTILITY(U,$J,358.3,26883,0)
+114 ;;=F63.3^^110^1294^8
+115 ;;^UTILITY(U,$J,358.3,26883,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,26883,1,3,0)
+118 ;;=3^Trichotillomania (Hair-Pulling D/O)
